BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477-483. [PMID: 21939925 DOI: 10.1016/j.crohns.2011.06.009] [Cited by in Crossref: 204] [Cited by in F6Publishing: 202] [Article Influence: 18.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim MC, Kim SH, Koh SJ, Park JH, Yoon H. Clinical implication of radiologic complete remission on Crohn's Disease: Compared with endoscopic remission. Eur J Radiol 2022;155:110469. [PMID: 35988393 DOI: 10.1016/j.ejrad.2022.110469] [Reference Citation Analysis]
2 Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
3 Kim KO. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice. Clin Endosc 2022;55:480-8. [PMID: 35898147 DOI: 10.5946/ce.2022.108] [Reference Citation Analysis]
4 Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, economic and quality-of-life outcomes. Curr Med Res Opin 2022;:1-40. [PMID: 35608153 DOI: 10.1080/03007995.2022.2081453] [Reference Citation Analysis]
5 Kawashima K, Oshima N, Kishimoto K, Kataoka M, Fukunaga M, Kotani S, Sonoyama H, Oka A, Mishima Y, Kazumori H, Ishikawa N, Araki A, Ishihara S. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission. Inflamm Bowel Dis 2022:izac095. [PMID: 35583193 DOI: 10.1093/ibd/izac095] [Reference Citation Analysis]
6 Gui X, Bazarova A, Del Amor R, Vieth M, de Hertogh G, Villanacci V, Zardo D, Parigi TL, Røyset ES, Shivaji UN, Monica MAT, Mandelli G, Bhandari P, Danese S, Ferraz JG, Hayee B, Lazarev M, Parra-Blanco A, Pastorelli L, Panaccione R, Rath T, Tontini GE, Kiesslich R, Bisschops R, Grisan E, Naranjo V, Ghosh S, Iacucci M. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. Gut 2022;71:889-98. [PMID: 35173041 DOI: 10.1136/gutjnl-2021-326376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
8 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Watanabe J, Furukawa S, Yagi S, Shiraishi K, Hanayama M, Tange K, Hashimoto Y, Kitahata S, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Time spent per day in strenuous activity and total physical activity are inversely associated with mucosal healing but not with clinical remission in patients with ulcerative colitis. Ann Gastroenterol 2021;34:796-801. [PMID: 34815645 DOI: 10.20524/aog.2021.0663] [Reference Citation Analysis]
10 Furukawa S, Ikeda Y, Yagi S, Miyake T, Shiraishi K, Tange K, Hashimoto Y, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Hiasa Y. Association Between Peripheral Blood Monocyte Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis. Clin Transl Gastroenterol 2021;12:e00429. [PMID: 34797817 DOI: 10.14309/ctg.0000000000000429] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Christensen KR, Steenholdt C, Buhl S, Brynskov J, Ainsworth MA. A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence. Scand J Gastroenterol 2021;:1-8. [PMID: 34779308 DOI: 10.1080/00365521.2021.2002397] [Reference Citation Analysis]
12 Xiang BJ, Jiang M, Sun MJ, Dai C. Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Visc Med 2021;37:338-48. [PMID: 34722717 DOI: 10.1159/000514196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart AH, Silverberg MS, Narula N. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients. Eur J Gastroenterol Hepatol 2021;33:1274-9. [PMID: 34402466 DOI: 10.1097/MEG.0000000000002250] [Reference Citation Analysis]
14 Takabayashi K, Hosoe N, Kato M, Hayashi Y, Miyanaga R, Nanki K, Fukuhara K, Mikami Y, Mizuno S, Sujino T, Mutaguchi M, Naganuma M, Yahagi N, Ogata H, Kanai T. Efficacy of Novel Ultrathin Single-Balloon Enteroscopy for Crohn's Disease: A Propensity Score-Matched Study. Gut Liver 2020;14:619-25. [PMID: 31818049 DOI: 10.5009/gnl19228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A, Carneiro F, Rosini F, de Hertogh G, Biedermann L, Pouillon L, Scharl M, Tripathi M, Danese S, Villanacci V, Feakins R. ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. J Crohns Colitis 2020;14:1503-11. [PMID: 32504534 DOI: 10.1093/ecco-jcc/jjaa110] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
16 Rocha R, de J Santos G, Santana G. Influence of nutritional status in the postoperative period of patients with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2021; 12(5): 90-99 [PMID: 34616585 DOI: 10.4292/wjgpt.v12.i5.90] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Miyazu T, Ishida N, Takano R, Tamura S, Yamade M, Hamaya Y, Tani S, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission. Medicine (Baltimore) 2021;100:e26550. [PMID: 34398010 DOI: 10.1097/MD.0000000000026550] [Reference Citation Analysis]
18 Gong W, Guo K, Zheng T, Xie H, Li W, Li M, Hong Z, Ren H, Gu G, Wang G, Wu X, Ren J. JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease. Eur J Gastroenterol Hepatol 2021;33:1049-54. [PMID: 33136728 DOI: 10.1097/MEG.0000000000001979] [Reference Citation Analysis]
19 Noh SM, Oh EH, Park SH, Lee JB, Kim JY, Park JC, Kim J, Ham NS, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1231-40. [PMID: 32157278 DOI: 10.1093/ecco-jcc/jjaa042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Takenaka K, Kawamoto A, Hibiya S, Suzuki K, Fujii T, Motobayashi M, Shimizu H, Nagahori M, Saito E, Okamoto R, Watanabe M, Ohtsuka K. Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Aliment Pharmacol Ther 2021. [PMID: 34323301 DOI: 10.1111/apt.16551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, Ceccarelli L, Bellini M, Marchi S, Costa F. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol 2020;32:1091-8. [PMID: 32282400 DOI: 10.1097/MEG.0000000000001731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
22 Köker IH, Gultepe BS, Kiremitçi S, Koçhan K, Ince AT, Keskin EB, Senturk H. Can serum histone H4 levels predict mucosal healing in Crohn's disease? Prz Gastroenterol 2021;16:127-31. [PMID: 34276839 DOI: 10.5114/pg.2021.106663] [Reference Citation Analysis]
23 Kim MJ, Kim E, Kang B, Choe YH. Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:870-6. [PMID: 33908743 DOI: 10.1097/MPG.0000000000003070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Barberio B, Zingone F, D'Incà R, Rovigo L, Bertani L, Bodini G, Ghisa M, Gubbiotti A, Massimi D, Lorenzon G, Savarino EV. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Clin Transl Gastroenterol 2020;11:e00177. [PMID: 32677808 DOI: 10.14309/ctg.0000000000000177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
25 Furukawa S, Yagi S, Shiraishi K, Hashimoto Y, Kitahata S, Hanayama M, Tange K, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. The inverse association between unhealthy eating habit and mucosal healing among patients with ulcerative colitis. BMC Gastroenterol 2021;21:152. [PMID: 33827432 DOI: 10.1186/s12876-021-01724-6] [Reference Citation Analysis]
26 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
27 Shiraishi K, Furukawa S, Yagi S, Mori K, Ninomiya T, Kawasaki K, Mizukami Y, Suzuki S, Uraoka M, Shibata N, Nakamura S, Imamine S, Murakami H, Ohashi K, Torisu M, Yano M, Hasebe A, Yano H, Murakami M, Takeshita E, Ikeda Y, Hiasa Y. Serum Globulin Is Associated with Endoscopic Findings and Mucosal Healing in Japanese Patients with Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 33537920 DOI: 10.1007/s10620-021-06834-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
28 Taberner Bonastre P, Torres Vicente G, Cano-Marron M, Sese Abizanda E, Volta Pardo TD, Schoenenberger-Arnaiz JA. A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib. Eur J Hosp Pharm 2021:ejhpharm-2020-002437. [PMID: 33495165 DOI: 10.1136/ejhpharm-2020-002437] [Reference Citation Analysis]
29 Kitazume Y, Takenaka K, Ohtsuka K, Kimura K, Ogihara Y, Fujioka T, Tsuchiya J, Fujii T, Watanabe M, Tateisi U. Crohn disease: magnetic resonance enterocolonography features of endoscopic ulcer stages reclassified with the healing process and the relationships to prognoses. Jpn J Radiol 2021;39:459-76. [PMID: 33438096 DOI: 10.1007/s11604-020-01082-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Furukawa S, Yagi S, Shiraishi K, Mori K, Ninomiya T, Kawasaki K, Mizukami Y, Suzuki S, Uraoka M, Shibata N, Nakamura S, Imamine S, Murakami H, Ohashi K, Torisu M, Hasebe A, Yano H, Murakami M, Takeshita E, Ikeda Y, Hiasa Y. Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. BMC Gastroenterol 2020;20:384. [PMID: 33198664 DOI: 10.1186/s12876-020-01538-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Shiraishi K, Furukawa S, Yagi S, Hanayama M, Mori K, Ninomiya T, Suzuki S, Ohashi K, Murakami H, Takeshita E, Ikeda Y, Hiasa Y. Association between serum bilirubin and mucosal healing among Japanese patients with ulcerative colitis: a cross-sectional study. Int J Colorectal Dis 2021;36:377-82. [PMID: 33040190 DOI: 10.1007/s00384-020-03774-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
33 Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol 2020;13:1756284820944088. [PMID: 32782481 DOI: 10.1177/1756284820944088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Principi M, Labarile N, Bianchi FP, Contaldo A, Tafuri S, Ierardi E, Di Leo A. The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. Int J Environ Res Public Health 2020;17:E4549. [PMID: 32599816 DOI: 10.3390/ijerph17124549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
36 d'Aldebert E, Quaranta M, Sébert M, Bonnet D, Kirzin S, Portier G, Duffas JP, Chabot S, Lluel P, Allart S, Ferrand A, Alric L, Racaud-Sultan C, Mas E, Deraison C, Vergnolle N. Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients. Front Cell Dev Biol 2020;8:363. [PMID: 32582690 DOI: 10.3389/fcell.2020.00363] [Cited by in Crossref: 22] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
37 Chateau T, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.Am J Gastroenterol. 2020;115:179-189. [PMID: 31809296 DOI: 10.14309/ajg.0000000000000437] [Cited by in Crossref: 15] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
38 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
39 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
40 Mennillo E, Yang X, Paszek M, Auwerx J, Benner C, Chen S. NCoR1 Protects Mice From Dextran Sodium Sulfate-Induced Colitis by Guarding Colonic Crypt Cells From Luminal Insult. Cell Mol Gastroenterol Hepatol 2020;10:133-47. [PMID: 32044398 DOI: 10.1016/j.jcmgh.2020.01.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Kim ES, Lee HS, Kim SK, Kim EY, Jang BI, Kim KO, Yang CH, Lee YJ; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study. Scand J Gastroenterol 2020;55:163-8. [PMID: 31984815 DOI: 10.1080/00365521.2020.1714716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
42 Honzawa Y, Matsuura M, Higuchi H, Sakurai T, Seno H, Nakase H. A novel endoscopic imaging system for quantitative evaluation of colonic mucosal inflammation in patients with quiescent ulcerative colitis. Endosc Int Open 2020;8:E41-9. [PMID: 31921983 DOI: 10.1055/a-0990-9375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
43 de Jong MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, Romberg-Camps M, Hameeteman W, Bodelier AGL, Romanko I, Lukas M, Winkens B, Markus T, Masclee AAM, van Tubergen A, Jonkers DMAE, Pierik MJ. Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease. J Crohns Colitis. 2019;13:555-563. [PMID: 30476099 DOI: 10.1093/ecco-jcc/jjy196] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
44 van Bodegraven AA, Bravenboer N. Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int 2020;31:637-46. [PMID: 31822927 DOI: 10.1007/s00198-019-05234-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
45 Goll R, Heitmann R, Moe ØK, Carlsen K, Florholmen J. Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis. PLoS One 2019;14:e0224895. [PMID: 31790426 DOI: 10.1371/journal.pone.0224895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Kim J, Kim SH, Kim TO. Evaluation of CT enterography findings for endoscopic complete remission after anti-TNF-α therapy in patients with Crohn's disease. Acta Radiol 2019;60:1200-8. [PMID: 30628841 DOI: 10.1177/0284185118820062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Ryu DG, Kim HW, Park SB, Kang DH, Choi CW, Kim SJ, Nam HS. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis. Medicine (Baltimore). 2019;98:e17080. [PMID: 31490411 DOI: 10.1097/md.0000000000017080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
48 Klenske E, Atreya R, Hartmann A, Fischer S, Hirschmann S, Zundler S, Iaccuci M, Neurath MF, Rath T. Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease. Endosc Int Open 2019;7:E1018-26. [PMID: 31404439 DOI: 10.1055/a-0953-1334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 Salem F, Kindt N, Marchesi JR, Netter P, Lopez A, Kokten T, Danese S, Jouzeau JY, Peyrin-Biroulet L, Moulin D. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. United European Gastroenterol J 2019;7:1008-32. [PMID: 31662859 DOI: 10.1177/2050640619867555] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
50 Batura V, Muise AM. Very early onset IBD: novel genetic aetiologies. Curr Opin Allergy Clin Immunol 2018;18:470-80. [PMID: 30299396 DOI: 10.1097/ACI.0000000000000486] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
51 Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, Hong Z, Ren H, Gu G, Wang G, Wu X, Wang Z, Ren J, Li J. Correlation between endoscopic and histological validated scoring indices in Crohn’s disease. Digestive and Liver Disease 2019;51:812-7. [DOI: 10.1016/j.dld.2019.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
52 Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis. 2019;13:189-197. [PMID: 30452616 DOI: 10.1093/ecco-jcc/jjy155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
53 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 van der Giessen J, van der Woude CJ, Peppelenbosch MP, Fuhler GM. A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models. Cells. 2019;8. [PMID: 30893871 DOI: 10.3390/cells8030261] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
55 Castiglione F, Imperatore N, Testa A, De Palma GD, Nardone OM, Pellegrini L, Caporaso N, Rispo A. One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther 2019;49:1026-39. [DOI: 10.1111/apt.15190] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 19.0] [Reference Citation Analysis]
56 Sonoyama H, Kawashima K, Ishihara S, Kotani S, Fukuba N, Oka A, Kusunoki R, Tada Y, Mishima Y, Oshima N, Moriyama I, Yuki T, Onishi K, Kinoshita Y. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr 2019;64:265-70. [PMID: 31138962 DOI: 10.3164/jcbn.18-92] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
57 Thierry ML, Rousseau H, Pouillon L, Girard-Gavanier M, Baumann C, Lopez A, Danese S, Laurent V, Peyrin-Biroulet L. Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018;12:1180-1190. [PMID: 29985999 DOI: 10.1093/ecco-jcc/jjy098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
58 White JR, Jairath V, Moran GW. Evolution of treatment targets in Crohn's disease. Best Pract Res Clin Gastroenterol 2019;38-39:101599. [PMID: 31327410 DOI: 10.1016/j.bpg.2019.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 783] [Article Influence: 170.5] [Reference Citation Analysis]
60 Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol 2018; 24(47): 5322-5330 [PMID: 30598577 DOI: 10.3748/wjg.v24.i47.5322] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
61 Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, Acra S. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018;11:CD012774. [PMID: 30480772 DOI: 10.1002/14651858.CD012774.pub2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 72] [Article Influence: 9.8] [Reference Citation Analysis]
62 Nakarai A, Kato J, Hiraoka S, Takashima S, Inokuchi T, Takahara M, Sugihara Y, Harada K, Okada H. An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing. Gut Liver. 2018;12:420-425. [PMID: 29945423 DOI: 10.5009/gnl17236] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
63 Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa T, Furukawa K, Ohno E, Kawashima H, Miyahara R, Koulaouzidis A, Hirooka Y; Nagoya University Crohn’s Disease Study Group. Validity of Capsule Endoscopy in Monitoring Therapeutic Interventions in Patients with Crohn's Disease. J Clin Med 2018;7:E311. [PMID: 30274238 DOI: 10.3390/jcm7100311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
64 Hiraoka S, Inokuchi T, Nakarai A, Takashima S, Takei D, Sugihara Y, Takahara M, Harada K, Okada H, Kato J. Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis. Gut Liver 2018;12:142-8. [PMID: 28873508 DOI: 10.5009/gnl17013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
65 Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. World J Gastroenterol 2018; 24(35): 4014-4020 [PMID: 30254405 DOI: 10.3748/wjg.v24.i35.4014] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
66 Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2018;. [PMID: 30130840 DOI: 10.5946/ce.2018.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
67 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
68 Nakarai A, Hiraoka S, Takahashi S, Inaba T, Higashi R, Mizuno M, Takashima S, Inokuchi T, Sugihara Y, Takahara M, Harada K, Kato J, Okada H. Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse. J Crohns Colitis. 2018;12:71-76. [PMID: 28961792 DOI: 10.1093/ecco-jcc/jjx118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
69 Chang JY, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation? Dig Dis Sci 2018;63:3041-8. [PMID: 29987626 DOI: 10.1007/s10620-018-5193-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1425-1433. [PMID: 28570431 DOI: 10.1097/mib.0000000000001140] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 23.0] [Reference Citation Analysis]
71 Hibi T, Panaccione R, Katafuchi M, Yokoyama K, Watanabe K, Matsui T, Matsumoto T, Travis S, Suzuki Y. The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management. J Crohns Colitis. 2017;11:1302-1308. [PMID: 28981622 DOI: 10.1093/ecco-jcc/jjx085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
72 Kawashima K, Ishihara S, Yuki T, Fukuba N, Sonoyama H, Kazumori H, Yamashita N, Tada Y, Kusunoki R, Oka A, Oshima N, Mishima Y, Moriyama I, Kinoshita Y. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy. Inflamm Bowel Dis 2017;23:2027-34. [PMID: 28817462 DOI: 10.1097/MIB.0000000000001202] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
73 Tontini GE, Mudter J, Vieth M, Günther C, Milani V, Atreya R, Rath T, Nägel A, Hatem G, Sturniolo GC, Vecchi M, Neurath MF, Galle PR, Buda A, Neumann H. Prediction of clinical outcomes in Crohn’s disease by using confocal laser endomicroscopy: results from a prospective multicenter study. Gastrointestinal Endoscopy 2018;87:1505-1514.e3. [DOI: 10.1016/j.gie.2017.10.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
74 Lopes S, Andrade P, Afonso J, Cunha R, Rodrigues-Pinto E, Ramos I, Macedo G, Magro F. Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. Therap Adv Gastroenterol 2018;11:1756284818769075. [PMID: 29760785 DOI: 10.1177/1756284818769075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
75 Sasanuma S, Ohtsuka K, Kudo SE, Ogata N, Maeda Y, Misawa M, Mori Y, Kudo T, Hisayuki T, Wakamura K, Hayashi T, Katagiri A, Miyachi H, Baba T, Ishida F. Narrow band imaging efficiency in evaluation of mucosal healing/relapse of ulcerative colitis. Endosc Int Open 2018;6:E518-23. [PMID: 29713677 DOI: 10.1055/s-0044-102297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
76 Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa J, Wallace K, Lacerda A, Thakkar RB, Robinson AM. Performance of Crohn’s disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. Inflammatory Bowel Diseases 2018;24:932-42. [DOI: 10.1093/ibd/izx082] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
77 Yoshimura T, Hirooka Y, Nakamura M, Watanabe O, Yamamura T, Matsushita M, Ishikawa T, Furukawa K, Funasaka K, Ohno E, Kawashima H, Miyahara R, Goto H. Clinical significance of gastrointestinal patency evaluation by using patency capsule in Crohn's disease. Nagoya J Med Sci 2018;80:121-8. [PMID: 29581621 DOI: 10.18999/nagjms.80.1.121] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
78 Laurent V, Naudé S, Vuitton L, Zallot C, Baumann C, Girard-Gavanier M, Peyrin-Biroulet L. Accuracy of Diffusion-weighted Magnetic Resonance Colonography in Assessing Mucosal Healing and the Treatment Response in Patients with Ulcerative Colitis. J Crohns Colitis 2017;11:716-23. [PMID: 27932450 DOI: 10.1093/ecco-jcc/jjw211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
79 Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY. Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:858-65. [PMID: 28509817 DOI: 10.1097/MIB.0000000000001152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
80 Dai C, Jiang M, Sun M, Cao Q. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis: Fecal markers in ulcerative colitis. Journal of Gastroenterology and Hepatology 2018;33:990-7. [DOI: 10.1111/jgh.14121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
81 Li XH, Sun CH, Mao R, Huang SY, Zhang ZW, Yang XF, Huang L, Lin JJ, Zhang J, Ben-Horin S, Feng ST, Chen MH, Li ZP. Diffusion-weighted MRI Enables to Accurately Grade Inflammatory Activity in Patients of Ileocolonic Crohn's Disease: Results from an Observational Study. Inflamm Bowel Dis. 2017;23:244-253. [PMID: 28079618 DOI: 10.1097/mib.0000000000001001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
82 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol 2018;9:136. [PMID: 29491393 DOI: 10.1038/s41424-018-0006-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
83 Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D; le GETAID. Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. Inflamm Bowel Dis 2016;22:1362-9. [PMID: 26919458 DOI: 10.1097/MIB.0000000000000741] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
84 Nyabanga C, Kochhar G, Costa G, Soliman B, Shen B, Abu-Elmagd K. Management of Crohn's Disease in the New Era of Gut Rehabilitation and Intestinal Transplantation. Inflamm Bowel Dis 2016;22:1763-76. [PMID: 27104827 DOI: 10.1097/MIB.0000000000000792] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
85 Marchal Bressenot A. Which evidence for a treat to target strategy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:3-8. [DOI: 10.1016/j.bpg.2018.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
86 Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med. 2019;34:72-80. [PMID: 29347813 DOI: 10.3904/kjim.2016.324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
87 Galgut BJ, Lemberg DA, Day AS, Leach ST. The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases. Front Pediatr 2017;5:292. [PMID: 29404311 DOI: 10.3389/fped.2017.00292] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
88 Ishihara S, Tada Y, Kawashima K, Kataoka M, Sonoyama H, Yamashita N, Oka A, Kusunoki R, Fukuba N, Mishima Y, Oshima N, Moriyama I, Yuki T, Kinoshita Y. Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease-Possible biomarker for evaluating mucosal healing. Dig Liver Dis 2018;50:553-8. [PMID: 29311027 DOI: 10.1016/j.dld.2017.12.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
89 Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Nagahori M, Fujii T, Saito E, Kimura M, Fujioka T, Watanabe M. Utility of Magnetic Resonance Enterography For Small Bowel Endoscopic Healing in Patients With Crohn's Disease. Am J Gastroenterol 2018;113:283-94. [PMID: 29257147 DOI: 10.1038/ajg.2017.464] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
90 Holmberg FE, Seidelin JB, Yin X, Mead BE, Tong Z, Li Y, Karp JM, Nielsen OH. Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. EMBO Mol Med. 2017;9:558-570. [PMID: 28283650 DOI: 10.15252/emmm.201607260] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
91 Calafat M, Lobatón T, Hernández-gallego A, Mañosa M, Torres P, Cañete F, Cabré E, Ojanguren I, Domènech E. Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission. Digestive and Liver Disease 2017;49:1327-31. [DOI: 10.1016/j.dld.2017.08.041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
92 Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396 [PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 36] [Article Influence: 9.2] [Reference Citation Analysis]
93 Lee SH, Kim MJ, Chang K, Song EM, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol 2017;17:110. [PMID: 29061121 DOI: 10.1186/s12876-017-0669-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
94 Scoville EA, Schwartz DA. Endoscopy in inflammatory bowel disease: advances in disease management. Gastrointest Endosc 2017;86:952-61. [PMID: 28886962 DOI: 10.1016/j.gie.2017.08.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Maconi G, Armuzzi A. Beyond remission and mucosal healing in Crohn's disease. Exploring the deep with cross sectional imaging. Dig Liver Dis. 2017;49:457-458. [PMID: 28449813 DOI: 10.1016/j.dld.2017.04.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
96 Santha SL, Shankar PR, Pan A, Schoen B, Kugathasan S, Sauer CG. Mucosal Healing in Clinical Practice: A Single-Center Pediatric IBD Experience. Inflammatory Bowel Diseases 2017;23:1447-53. [DOI: 10.1097/mib.0000000000001176] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
97 Marchal A. Histoséminaire sur les maladies inflammatoires chroniques intestinales (MICI) : cas n o  05 et 06. Annales de Pathologie 2017;37:302-7. [DOI: 10.1016/j.annpat.2017.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Ye L, Chen BQ, Wang SD, Shi H, Yang Z, Wang FY. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study. Scand J Gastroenterol 2017;52:1113-9. [PMID: 28675068 DOI: 10.1080/00365521.2017.1346704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
99 Oh K, Oh EH, Baek S, Song EM, Kim GU, Seo M, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One. 2017;12:e0179266. [PMID: 28622356 DOI: 10.1371/journal.pone.0179266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
100 Yang Q, Gao X, Chen H, Li M, Wu X, Zhi M, Lan P, Hu P. Efficacy of exclusive enteral nutrition in complicated Crohn's disease. Scand J Gastroenterol. 2017;52:995-1001. [PMID: 28598298 DOI: 10.1080/00365521.2017.1335770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
101 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 158] [Article Influence: 34.4] [Reference Citation Analysis]
102 Allen PB, Olivera P, Emery P, Moulin D, Jouzeau J, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-biroulet L. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther 2017;45:1058-72. [DOI: 10.1111/apt.13995] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
103 Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J. 2016;57:1376-1385. [PMID: 27593865 DOI: 10.3349/ymj.2016.57.6.1376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
104 Maréchal C, Aimone-Gastin I, Baumann C, Dirrenberger B, Guéant JL, Peyrin-Biroulet L. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United European Gastroenterol J 2017;5:702-7. [PMID: 28815034 DOI: 10.1177/2050640616686517] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
105 Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801-813. [PMID: 28112419 DOI: 10.1111/apt.13948] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 13.4] [Reference Citation Analysis]
106 Calabrese E, Maaser C, Zorzi F, Kannengiesser K, Hanauer SB, Bruining DH, Iacucci M, Maconi G, Novak KL, Panaccione R, Strobel D, Wilson SR, Watanabe M, Pallone F, Ghosh S. Bowel Ultrasonography in the Management of Crohn's Disease. Inflamm Bowel Dis. 2016;22:1168-1183. [PMID: 26958988 DOI: 10.1097/mib.0000000000000706] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 18.2] [Reference Citation Analysis]
107 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
108 Sawadsopanon T, Meksawan K, Chanvorachote P. Aspartame inhibits migration of human intestinal epithelial cells: SAWADSOPANON et al. Journal of Food Biochemistry 2017;41:e12341. [DOI: 10.1111/jfbc.12341] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
109 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
110 Ellinger S. Can specific nutrients stimulate bowel wound healing? Curr Opin Clin Nutr Metab Care 2016;19:371-6. [PMID: 27348151 DOI: 10.1097/MCO.0000000000000303] [Reference Citation Analysis]
111 Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 2016;65:1447-55. [PMID: 26353983 DOI: 10.1136/gutjnl-2015-309903] [Cited by in Crossref: 106] [Cited by in F6Publishing: 106] [Article Influence: 17.7] [Reference Citation Analysis]
112 Basaranoglu M, Ertan A, Mathew S, Najjar SM, Ala A, Demirbag AE, Senturk H. Rate and Predictors of Endoscopic Mucosal Healing in Biologic Naive Patients with Inflammatory Bowel Disease by Azathioprine Treatment: A Real World, 10 Years' Experience from a Single Centre in Turkey. J Gastrointest Dig Syst 2016;6:467. [PMID: 29057149 DOI: 10.4172/2161-069X.1000467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44:495-504. [PMID: 27402063 DOI: 10.1111/apt.13731] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
114 Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. J Crohns Colitis. 2017;11:53-59. [PMID: 27402915 DOI: 10.1093/ecco-jcc/jjw122] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
115 Blander JM. Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J. 2016;283:2720-2730. [PMID: 27250564 DOI: 10.1111/febs.13771] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 13.8] [Reference Citation Analysis]
116 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
117 Pehlivaner Kara MO, Ekenseair AK. In situ spray deposition of cell-loaded, thermally and chemically gelling hydrogel coatings for tissue regeneration: IN SITU SPRAY DEPOSITION OF HYDROGEL COATINGS FOR TISSUE REGENERATION. J Biomed Mater Res 2016;104:2383-93. [DOI: 10.1002/jbm.a.35774] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
118 Inokuchi T, Kato J, Hiraoka S, Takashima S, Nakarai A, Takei D, Sugihara Y, Takahara M, Kawano S, Harada K, Okada H. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohnʼs Disease: . Inflammatory Bowel Diseases 2016;22:1078-85. [DOI: 10.1097/mib.0000000000000728] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
119 Pineton de Chambrun G, Blanc P, Peyrin-biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2016. [DOI: 10.1586/17474124.2016.1174064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
120 Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
121 Fron C, Pierry C, Poullenot F, Chabrun E, Subtil C, Capdepont M, Zerbib F, Belleannée G, Laharie D. Endoscopic and histologic response to cyclosporine in ulcerative colitis and their impact on disease outcome: A cohort study. Dig Liver Dis 2016;48:734-9. [PMID: 27052254 DOI: 10.1016/j.dld.2016.03.007] [Reference Citation Analysis]
122 Kim C, Park SH, Yang SK, Ye BD, Park SH, Lee JS, Kim HJ, Kim AY, Ha HK. Endoscopic Complete Remission of Crohn Disease After Anti-Tumor Necrosis Factor-α Therapy: CT Enterographic Findings and Their Clinical Implications. AJR Am J Roentgenol 2016;206:1208-16. [PMID: 26998628 DOI: 10.2214/AJR.15.15256] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
123 Zakko SF, Gordon GL, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. Postgrad Med. 2016;128:273-281. [PMID: 26861051 DOI: 10.1080/00325481.2016.1152876] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
124 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016;65:408-14. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 219] [Cited by in F6Publishing: 210] [Article Influence: 36.5] [Reference Citation Analysis]
125 Allen PB, Peyrin-Biroulet L. Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. Expert Rev Clin Immunol. 2016;12:741-749. [PMID: 26900725 DOI: 10.1586/1744666x.2016.1154789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Ikhtaire S, Shajib MS, Reinisch W, Khan WI. Fecal calprotectin: Its scope and utility in the management of inflammatory bowel disease. J Gastroenterol. 2016;51:434-446. [PMID: 26897740 DOI: 10.1007/s00535-016-1182-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
127 Zhang Y, Li WH, Lv YG. Intermittent fever and developmental retardation as initial manifestations in a pediatric Crohn's disease patient: A case report and literature review. Shijie Huaren Xiaohua Zazhi 2016; 24(5): 821-826 [DOI: 10.11569/wcjd.v24.i5.821] [Reference Citation Analysis]
128 Suzuki Y, Uchiyama K, Kato M, Matsuo K, Nakagawa T, Kishikawa H, Kimura N, Kasanuki J, Ino S. Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation. J Clin Gastroenterol 2015;49:401-6. [PMID: 25127112 DOI: 10.1097/MCG.0000000000000199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
129 Takahashi F, Tominaga K, Kanamori A, Takenaka K, Hoshino A, Sugaya T, Nakano M, Hiraishi H. Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis. Scandinavian Journal of Gastroenterology 2016;51:827-34. [DOI: 10.3109/00365521.2016.1141315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
130 Hiraoka S, Kato J, Nakarai A, Takashima S, Inokuchi T, Takei D, Sugihara Y, Takahara M, Harada K, Okada H. Consecutive Measurements by Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Detect Clinical Relapse. ECCOJC 2016;10:687-94. [DOI: 10.1093/ecco-jcc/jjw025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
131 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
132 Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology 2016;150:96-102. [PMID: 26376350 DOI: 10.1053/j.gastro.2015.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
133 Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bastón I, Ferreiro-Iglesias R, Lorenzo A, Domínguez-Muñoz JE. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns Colitis 2016;10:13-9. [PMID: 26351390 DOI: 10.1093/ecco-jcc/jjv158] [Cited by in Crossref: 92] [Cited by in F6Publishing: 104] [Article Influence: 13.1] [Reference Citation Analysis]
134 Quénéhervé L, Neunlist M, Bruley des Varannes S, Tearney G, Coron E. [Novel endoscopic techniques to image the upper gastrointestinal tract]. Med Sci (Paris) 2015;31:777-83. [PMID: 26340838 DOI: 10.1051/medsci/20153108017] [Reference Citation Analysis]
135 Singh S, Loftus EV Jr. Crohn's disease: REACT to save the gut. Lancet 2015;386:1800-2. [PMID: 26342730 DOI: 10.1016/S0140-6736(15)00069-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
136 Danese S, Peyrin-Biroulet L, Fiorino G. Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball? Gut 2015;64:1347-8. [PMID: 25631668 DOI: 10.1136/gutjnl-2014-308919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
137 Marchal Bressenot A, Riddell RH, Boulagnon-Rombi C, Reinisch W, Danese S, Schreiber S, Peyrin-Biroulet L. Review article: the histological assessment of disease activity in ulcerative colitis. Aliment Pharmacol Ther. 2015;42:957-967. [PMID: 26304292 DOI: 10.1111/apt.13375] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
138 Nuti F, Civitelli F, Bloise S, Oliva S, Aloi M, Latorre G, Viola F, Cucchiara S. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort. J Crohns Colitis 2016;10:5-12. [PMID: 26188350 DOI: 10.1093/ecco-jcc/jjv126] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
139 Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2016;51:11-21. [PMID: 26138071 DOI: 10.1007/s00535-015-1098-4] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 17.7] [Reference Citation Analysis]
140 Łodyga M, Eder P, Bartnik W, Gonciarz M, Kłopocka M, Linke K, Małecka-Panas E, Radwan P, Rydzewska G. New pharmaceuticals in inflammatory bowel disease. Prz Gastroenterol 2015;10:57-60. [PMID: 26557934 DOI: 10.5114/pg.2015.52702] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
141 Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H, Tanaka T, Yamamoto K. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. American Journal of Gastroenterology 2015;110:873-80. [DOI: 10.1038/ajg.2015.66] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 10.0] [Reference Citation Analysis]
142 Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-biroulet L; the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO). Clinical Trials in Ulcerative Colitis: A Historical Perspective. ECCOJC 2015;9:580-8. [DOI: 10.1093/ecco-jcc/jjv074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
143 Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014;28:325-9. [PMID: 24945187 DOI: 10.1155/2014/737349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
144 Nishiyama S, Oka S, Tanaka S, Sagami S, Nagai K, Ueno Y, Arihiro K, Chayama K. Clinical usefulness of endocytoscopy in the remission stage of ulcerative colitis: a pilot study. J Gastroenterol 2015;50:1087-93. [DOI: 10.1007/s00535-015-1059-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
145 Lasson A, Öhman L, Stotzer PO, Isaksson S, Überbacher O, Ung KA, Strid H. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterol J. 2015;3:72-79. [PMID: 25653861 DOI: 10.1177/2050640614560785] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
146 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
147 Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283x14553384] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
148 Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M, Markowitz J, Rosh J, Crandall WV, Heyman MB, Mack DR, Griffiths AM, Baker SS, Hyams JS, Kugathasan S, Denson LA. Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1037-48. [PMID: 24788216 DOI: 10.1097/MIB.0000000000000049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
149 Niv E, Fishman S, Kachman H, Arnon R, Dotan I. Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. Journal of Crohn's and Colitis 2014;8:1616-23. [DOI: 10.1016/j.crohns.2014.03.003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
150 Makharia GK. Quality of care in Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(4): 462-466 [PMID: 25400990 DOI: 10.4291/wjgp.v5.i4.462] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
151 Hindryckx P, Baert F, Hart A, Armuzzi A, Panès J, Peyrin-biroulet L. Clinical trials in luminal Crohn's disease: A historical perspective. Journal of Crohn's and Colitis 2014;8:1339-50. [DOI: 10.1016/j.crohns.2014.04.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
152 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 167] [Article Influence: 20.3] [Reference Citation Analysis]
153 Tursi A, Elisei W, Picchio M, Forti G, Penna A, Inchingolo CD, Nenna R, Brandimarte G. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. Clin Res Hepatol Gastroenterol. 2015;39:107-113. [PMID: 25176588 DOI: 10.1016/j.clinre.2014.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
154 Baudry C, Pariente B, Lourenço N, Simon M, Chirica M, Cattan P, Munoz-Bongrand N, Gornet JM, Allez M. Tailored treatment according to early post-surgery colonoscopy reduces clinical recurrence in Crohn’s disease: a retrospective study. Dig Liver Dis. 2014;46:887-892. [PMID: 25081846 DOI: 10.1016/j.dld.2014.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
155 Wolf D, D’Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, Lazar A, Zhou Q, Petersson J, Thakkar RB. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014;40:486-497. [PMID: 25041859 DOI: 10.1111/apt.12863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
156 Al-Hawary MM, Zimmermann EM, Hussain HK. MR imaging of the small bowel in Crohn disease. Magn Reson Imaging Clin N Am. 2014;22:13-22. [PMID: 24238129 DOI: 10.1016/j.mric.2013.09.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
157 Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014;43:457-478. [PMID: 25110253 DOI: 10.1016/j.gtc.2014.05.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
158 Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19:2568-2576. [PMID: 24013361 DOI: 10.1097/mib.0b013e3182a77b41] [Cited by in Crossref: 166] [Cited by in F6Publishing: 166] [Article Influence: 20.8] [Reference Citation Analysis]
159 Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One 2014;9:e99293. [PMID: 24932476 DOI: 10.1371/journal.pone.0099293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
160 Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol 2014;7:163-72. [PMID: 24899819 DOI: 10.2147/CEG.S45261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
161 Antunes O, Filippi J, Hébuterne X, Peyrin-Biroulet L. Treatment algorithms in Crohn’s - up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473-483. [PMID: 24913386 DOI: 10.1016/j.bpg.2014.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
162 Duchesne C, Faure P, Kohler F, Pingannaud MP, Bonnaud G, Devulder F, Abramowitz L, Boustière C, Peyrin-Biroulet L; CREGG (Club de Reflexion des cabinets et Groupes d’Hépato-Gastroentérologie). Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists. Dig Liver Dis 2014;46:675-81. [PMID: 24809234 DOI: 10.1016/j.dld.2014.04.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
163 Papi C, Aratari A. Mucosal healing as a treatment for IBD? Expert Review of Gastroenterology & Hepatology 2014;8:457-9. [DOI: 10.1586/17474124.2014.902302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
164 Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543-554. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
165 Dignass A, Stoynov S, Dorofeyev AE, Grigorieva GA, Tomsová E, Altorjay I, Tuculanu D, Bunganič I, Pokrotnieks J, Kupčinskas L, Dilger K, Greinwald R, Mueller R; International Budenofalk Study Group. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2014;8:970-80. [PMID: 24534142 DOI: 10.1016/j.crohns.2014.01.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
166 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
167 Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397-404. [PMID: 23695427 DOI: 10.1097/mog.0b013e3283622914] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
168 Peyrin–biroulet L. Deep Remission in Crohn's Disease: Is It the End of the Placebo Effect? Clinical Gastroenterology and Hepatology 2014;12:347. [DOI: 10.1016/j.cgh.2013.07.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
169 Bern EM, Bousvaros A. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum. Expert Review of Clinical Immunology 2014;9:117-27. [DOI: 10.1586/eci.12.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
170 Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95. [PMID: 23974954 DOI: 10.1136/gutjnl-2013-304984] [Cited by in Crossref: 324] [Cited by in F6Publishing: 292] [Article Influence: 40.5] [Reference Citation Analysis]
171 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 466] [Article Influence: 54.0] [Reference Citation Analysis]
172 Feakins RM. Ulcerative colitis or Crohn’s disease? Pitfalls and problems. Histopathology. 2014;64:317-335. [PMID: 24266813 DOI: 10.1111/his.12263] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
173 Hordonneau C, Buisson A, Scanzi J, Goutorbe F, Pereira B, Borderon C, Da Ines D, Montoriol PF, Garcier JM, Boyer L, Bommelaer G, Petitcolin V. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn's disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89-98. [PMID: 24247212 DOI: 10.1038/ajg.2013.385] [Cited by in Crossref: 146] [Cited by in F6Publishing: 139] [Article Influence: 16.2] [Reference Citation Analysis]
174 Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
175 Papi C, Fascì-Spurio F, Rogai F, Settesoldi A, Margagnoni G, Annese V. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis. 2013;45:978-985. [PMID: 24018244 DOI: 10.1016/j.dld.2013.07.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
176 Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 2014;8:200-207. [PMID: 24012063 DOI: 10.1016/j.crohns.2013.08.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
177 Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ; International Organization for the Study of Inflammatory Bowel Diseases. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013; 145: 978-986. e5. [PMID: 23954314 DOI: 10.1053/j.gastro.2013.08.010] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 11.7] [Reference Citation Analysis]
178 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 8.1] [Reference Citation Analysis]
179 Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929-34.e2. [PMID: 23911875 DOI: 10.1016/j.cgh.2013.07.022] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 12.2] [Reference Citation Analysis]
180 Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 414-22. e5. [PMID: 23856361 DOI: 10.1016/j.cgh.2013.06.019] [Cited by in Crossref: 168] [Cited by in F6Publishing: 150] [Article Influence: 18.7] [Reference Citation Analysis]
181 Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315. [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 89] [Article Influence: 8.7] [Reference Citation Analysis]
182 Chamaillard M, Chevaux JB, Peyrin-Biroulet L. Looking beyond histological healing in ulcerative colitis: towards the establishment of a molecular signature for quiescent but progressive disease. Gut 2013;62:959-60. [PMID: 23242120 DOI: 10.1136/gutjnl-2012-303765] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
183 Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
184 Cury DB, Mizsputen SJ, Versolato C, Miiji LO, Pereira E, Delboni MA, Schor N, Moss AC. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol 2013;282:66-70. [PMID: 23685388 DOI: 10.1016/j.cellimm.2013.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
185 Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013;11:991-996. [PMID: 23591275 DOI: 10.1016/j.cgh.2013.02.030] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 9.8] [Reference Citation Analysis]
186 Laharie D, Filippi J, Roblin X, Nancey S, Chevaux J, Hébuterne X, Flourié B, Capdepont M, Peyrin-biroulet L. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013;37:998-1004. [DOI: 10.1111/apt.12289] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 9.3] [Reference Citation Analysis]
187 Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, Peyrin-Biroulet L, Schoepfer A, Vatn M, Vavricka S. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677. [PMID: 23517932 DOI: 10.1016/j.crohns.2013.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
188 Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-51. [PMID: 23458890 DOI: 10.1038/nrgastro.2013.31] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
189 Lasson A, Simrén M, Stotzer P, Isaksson S, Öhman L, Strid H. Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:576-81. [DOI: 10.1097/mib.0b013e31827e78be] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
190 Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G. Histological healing in inflammatory bowel disease: A still unfulfilled promise. World J Gastroenterol 2013; 19(7): 968-978 [PMID: 23467585 DOI: 10.3748/wjg.v19.i7.968] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
191 Rismo R, Olsen T, Cui G, Paulssen EJ, Christiansen I, Johnsen K, Florholmen J, Goll R. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn’s disease. Scand J Gastroenterol. 2013;48:311-319. [PMID: 23302000 DOI: 10.3109/00365521.2012.758773] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
192 Buisson A, Joubert A, Montoriol PF, Da Ines D, Hordonneau C, Pereira B, Garcier JM, Bommelaer G, Petitcolin V. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn's disease. Aliment Pharmacol Ther. 2013;37:537-545. [PMID: 23289713 DOI: 10.1111/apt.12201] [Cited by in Crossref: 142] [Cited by in F6Publishing: 130] [Article Influence: 15.8] [Reference Citation Analysis]
193 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
194 Neumann H, Neurath MF. UCCIS—a reproducible tool to assess mucosal healing. Nat Rev Gastroenterol Hepatol 2012;9:692-4. [DOI: 10.1038/nrgastro.2012.198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
195 Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L. Mucosal healing with anti-TNF antibodies. Digestion. 2012;86 Suppl 1:16-22. [PMID: 23051722 DOI: 10.1159/000341957] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
196 Rismo R, Olsen T, Ciu G, Paulssen EJ, Christiansen I, Florholmen J, Goll R. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:1200-10. [DOI: 10.3109/00365521.2012.711853] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
197 Weizman AV, Silverberg MS. Have genomic discoveries in inflammatory bowel disease translated into clinical progress? Curr Gastroenterol Rep. 2012;14:139-145. [PMID: 22302508 DOI: 10.1007/s11894-012-0248-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
198 Lakatos PL, Lovasz BD, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Golovics PA, Vegh Z, Mandel M, Horvath A, Szathmari M, Kiss LS, Lakatos L. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2013;7:385-91. [PMID: 22766526 DOI: 10.1016/j.crohns.2012.06.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
199 Danese S, Peyrin-biroulet L. Mucosal healing—EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol 2012;9:309-11. [DOI: 10.1038/nrgastro.2012.77] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
200 Caprilli R, Latella G, Frieri G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick? J Crohns Colitis 2012;6:621-5. [PMID: 22425510 DOI: 10.1016/j.crohns.2012.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
201 Buisson A, Chevaux JB, Bommelaer G, Peyrin-Biroulet L. Diagnosis, prevention and treatment of postoperative Crohn’s disease recurrence. Dig Liver Dis. 2012;44:453-460. [PMID: 22265329 DOI: 10.1016/j.dld.2011.12.018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
202 Billioud V, Allen PB, Peyrin-Biroulet L. Update on Crohn's disease and ulcerative colitis. Expert Rev Gastroenterol Hepatol 2011;5:311-4. [PMID: 21651348 DOI: 10.1586/egh.11.35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
203 Matsuura R, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Suhara H, Furukawa K, Ishikawa T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Hirooka Y, Goto H. Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. Nagoya J Med Sci 2018;80:257-66. [PMID: 29915443 DOI: 10.18999/nagjms.80.2.257] [Cited by in F6Publishing: 2] [Reference Citation Analysis]